Cargando…

Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial

BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rashmi, Basu, Anirban, Sinha, Subrata, Das, Manoj, Tripathi, Piyush, Jain, Amita, Kumar, Chandrakanta, Atam, Virendra, Khan, Saima, Singh, Amit Shanker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743094/
https://www.ncbi.nlm.nih.gov/pubmed/26847071
http://dx.doi.org/10.1186/s12879-016-1385-6
_version_ 1782414295589453824
author Kumar, Rashmi
Basu, Anirban
Sinha, Subrata
Das, Manoj
Tripathi, Piyush
Jain, Amita
Kumar, Chandrakanta
Atam, Virendra
Khan, Saima
Singh, Amit Shanker
author_facet Kumar, Rashmi
Basu, Anirban
Sinha, Subrata
Das, Manoj
Tripathi, Piyush
Jain, Amita
Kumar, Chandrakanta
Atam, Virendra
Khan, Saima
Singh, Amit Shanker
author_sort Kumar, Rashmi
collection PubMed
description BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted. METHODS: Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was by intention to treat. RESULTS: 281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 · 1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow Outcome Score (GOS) at 3 months (χ(2) = 7 · 44, p = 0 · 059). These trends were further accentuated if patients dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07), p = 0.090; 3 month GOS p = 0 · 028]. CONCLUSIONS: A trend towards better outcomes was observed with minocycline, especially in those patients who survived the initial day in hospital. These findings should form the basis for planning a larger study and possibly including minocycline in the initial management of AES as seen here. TRIAL REGISTRATION: The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143
format Online
Article
Text
id pubmed-4743094
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47430942016-02-06 Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial Kumar, Rashmi Basu, Anirban Sinha, Subrata Das, Manoj Tripathi, Piyush Jain, Amita Kumar, Chandrakanta Atam, Virendra Khan, Saima Singh, Amit Shanker BMC Infect Dis Research Article BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted. METHODS: Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was by intention to treat. RESULTS: 281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 · 1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow Outcome Score (GOS) at 3 months (χ(2) = 7 · 44, p = 0 · 059). These trends were further accentuated if patients dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07), p = 0.090; 3 month GOS p = 0 · 028]. CONCLUSIONS: A trend towards better outcomes was observed with minocycline, especially in those patients who survived the initial day in hospital. These findings should form the basis for planning a larger study and possibly including minocycline in the initial management of AES as seen here. TRIAL REGISTRATION: The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143 BioMed Central 2016-02-04 /pmc/articles/PMC4743094/ /pubmed/26847071 http://dx.doi.org/10.1186/s12879-016-1385-6 Text en © Kumar et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kumar, Rashmi
Basu, Anirban
Sinha, Subrata
Das, Manoj
Tripathi, Piyush
Jain, Amita
Kumar, Chandrakanta
Atam, Virendra
Khan, Saima
Singh, Amit Shanker
Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title_full Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title_fullStr Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title_full_unstemmed Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title_short Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
title_sort role of oral minocycline in acute encephalitis syndrome in india – a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743094/
https://www.ncbi.nlm.nih.gov/pubmed/26847071
http://dx.doi.org/10.1186/s12879-016-1385-6
work_keys_str_mv AT kumarrashmi roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT basuanirban roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT sinhasubrata roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT dasmanoj roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT tripathipiyush roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT jainamita roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT kumarchandrakanta roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT atamvirendra roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT khansaima roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial
AT singhamitshanker roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial